Inhibitors of sodium-dependent phosphate transport

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 1, 2004, Pages 81-84

  Weinstock, Joseph ^a,b  

^a GLAXOSMITHKLINE   (United States)

^b NONE   (United States)

Author keywords

NaPi 3b; Phosphonoformic acid; Renal failure; Sevelamer; Sodium dependent phosphate transporter; Uremic bone disease

Indexed keywords

2' PHOSPHOPHLORETIN; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM FORMATE; CALCIUM SALT; FOSCARNET; LANTHANUM; LANTHANUM CARBONATE; PHLORETIN; PHOSPHATE; PHOSPHATE TRANSPORTER; PHOSPHATE TRANSPORTER INHIBITOR; PHYTIC ACID CALCIUM MAGNESIUM SALT; PROTEIN INHIBITOR; SEVELAMER; SODIUM; UNCLASSIFIED DRUG;

BONE DISEASE; CHRONIC KIDNEY DISEASE; DIALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INTESTINE ABSORPTION; KIDNEY FAILURE; NONHUMAN; PHOSPHATE BLOOD LEVEL; REVIEW; SECONDARY HYPERPARATHYROIDISM; UREMIA;

EID: 0347917044     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.1.81     Document Type: Review

References (5)

1. EDWARDS RM: Disorders of phosphate metabolism in chronic renal disease. Curr. Opin. Pharmac. (2002) 2:171-176.
2. HUTCHISON A, WEBSTER I, GILL M et al.: Safety tolerability and efficacy of lanthanum carbonate in haemodialysis patients: a 12-month study. The ERA-EDTA World Congress of Nephrology. Berlin, Germany (2003).
3. GENZYME CORP.: Renagel tablets. In: Physician Desk Reference, 57th Edition. Thomson PDR (Ed.), Montvale, NJ, USA (2003):1419-1421.
4. FIELD JA, ZHANG L, BRUN KA et al.: Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine. Biochem. Biophys. Res. Commun. (1999) 258:578-582.
5. FRANZ RG, GAITANOPOULOS D, GIRARD GR et al.: Inhibitors of phosphate transport. 225th ACS Meeting. New Orleans, USA (2003). MEDI 298.